PBA
MRUS

Paradigm Biocapital Advisors’s Merus MRUS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MRUS Stock Details MRUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300,000
Closed -$28.2M – 40
2025
Q3 		$28.2M Buy
+300,000
New +$19.5M 0.8% 28

Other funds holding MRUS

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $1.02B AUM 31.16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paradigm Biocapital Advisors's MRUS Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Merus (MRUS) in Q4 2025, closing a stake of 4,373,770 shares — an estimated $412M sold.

Paradigm Biocapital Advisors first reported a position in MRUS in Q1 2022 and held it in 9 quarters. The position peaked at $412M in Q3 2025. 10 funds tracked by Wall St. Rank hold MRUS as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Merus position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 4,373,770 Merus shares in Q4 2025, an estimated $412M.
  • Paradigm Biocapital Advisors first reported a position in Merus in Q1 2022 and held it in 9 quarters.
  • Paradigm Biocapital Advisors's Merus position peaked at $412M in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Merus as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.